Elsevier, a global leader in information and data analytics, has signed a multi-year agreement with Iktos, a company specialising in artificial intelligence for new drug discovery.
The partnership will strengthen Elsevier's flagship chemistry solution, Reaxys, by combining the company’s high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, said: “Our mission is to support research and development (R&D) organisations to fuel innovation and drug discovery with industry leading predictive algorithms trained on our high-quality data."
"We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help to reshape the landscape of small molecule discovery.”
The partnership aims to support R&D organisations to critically decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing the length and cost of early-stage drug discovery.
New predictive models will be launched to support use cases including retrosynthesis, synthetic accessibility and other reaction-based analyses.
The new tools will be delivered via Reaxys’ user-friendly interface and Application Programming Interface (APIs), accelerating research for synthetic, medicinal, computational and process chemistry teams at pharmaceutical, agrochemical and contract research organisations (CROs).
Yann Gaston-Mathé, CEO, Iktos, said: “Data is the foundation of AI, and we are very excited to partner with Elsevier. We will combine the strength of Reaxys, a chemistry reaction database with unmatched volume, diversity,and quality, with Iktos' leading edge retrosynthesis AI technology."
"We are committed to making our technology available to R&D organisations around the world to maximise the impact of AI on the productivity of drug discovery.”
